{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:46:32Z","timestamp":1782535592559,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Purpose: This study aims to determine the incidence of kidney injury associated with liposomal amphotericin B (L-AmB) treatment, based on RIFLE criteria, in patients admitted to the intensive care unit (ICU) with invasive pulmonary aspergillosis (IPA). Materials and Methods: A retrospective, multicenter observational study including patients treated with L-AmB for IPA while admitted to the ICU between 1 January 2015, and 31 December 2022. Results: A total of 65 patients were included. The prevalence of renal failure was 35.39%. Renal failure was mostly mild and reversible. The need for major surgery (OR 6.71; p = 0.121) and concomitant use of other nephrotoxic treatments (OR 2.5; p = 0.194) emerged as potential risk factors for the development of renal failure; however, neither association reached statistical significance. Overall mortality was 66.2%, significantly higher in the group with renal failure (82.6% vs. 57.1%; p = 0.03). Factors associated with mortality included concomitant use of other nephrotoxic agents (OR 4.51; p = 0.024) and development of renal failure (OR 3.66; p = 0.068). Duration of L-AmB treatment was not associated with mortality. Regarding creatinine recovery, all patients who developed renal failure but survived showed creatinine levels below 1.5 mg\/dL after completion of treatment. Conclusions: Renal impairment was common in this high-risk population of critically ill patients, with renal function impairment in one-third of exposed patients, although most cases were mild. In this population, concomitant administration of other nephrotoxic drugs was associated with both renal failure and mortality. Treatment duration with L-AmB was not linked to mortality, and creatinine levels normalized after therapy completion.<\/jats:p>","DOI":"10.3390\/jof12070458","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:03:23Z","timestamp":1782263003000},"page":"458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-Interventional, Retrospective, Multicenter Study on the Renal Safety of Liposomal Amphotericin B in Critically Ill Patients with Invasive Pulmonary Aspergillosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-3890","authenticated-orcid":false,"given":"Borja","family":"Suberviola","sequence":"first","affiliation":[{"name":"Intensive Care Department, University Hospital Marques de Valdecilla, Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-5383","authenticated-orcid":false,"given":"Jose Peral Gutierrez de","family":"Ceballos","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital Gregorio Mara\u00f1on, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose Asensio","family":"Martin","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital La Paz, IdiPAZ, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Soriano Cuesta","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-5486","authenticated-orcid":false,"given":"Rafael","family":"Zaragoza","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital Dr. Peset, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Forcelledo","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iratxe","family":"Seijas","sequence":"additional","affiliation":[{"name":"Intensive Care Department, University Hospital Cruces, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-615X","authenticated-orcid":false,"given":"Miguel","family":"Santibanez","sequence":"additional","affiliation":[{"name":"Global Health Research Group, Faculty of Nursing, Universidad de Cantabria-Valdecilla Research Institute (IDIVAL), Santander 39008, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41586-023-06710-4","article-title":"Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal","volume":"623","author":"Maji","year":"2023","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.riam.2021.02.001","article-title":"Clinical safety of liposomal amphotericin B","volume":"38","author":"Suberviola","year":"2021","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Lewis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","first-page":"CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: Effects on kidney function","volume":"11","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-4453(94)95956-0","article-title":"Liposomal amphotericin B, AmBisome","volume":"28","author":"Hay","year":"1994","journal-title":"J. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Peral, J., Estella, \u00c1., Nuvials, X., Rodr\u00edguez, A., Seijas, I., Soriano, C., Suberviola, B., and Zaragoza, R. (2023). Managing the Next Wave of Influenza and\/or SARS-CoV-2 in the ICU\u2014Practical Recommendations from an Expert Group for CAPA\/IAPA Patients. J. Fungi, 9.","DOI":"10.3390\/jof9030312"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s44158-025-00236-z","article-title":"Role of liposomal amphotericin B in intensive care unit: An expert opinion paper","volume":"5","author":"Bussini","year":"2025","journal-title":"J. Anesth. Analg. Crit. Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Valerio, M., Vena, A., Bouza, E., Reiter, N., Viale, P., Hochreiter, M., Giannella, M., Mu\u00f1oz, P., and COMIC Study Group (2015). How much European prescribing physicians know about invasive fungal infections management?. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0809-z"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","article-title":"Amphotericin B-induced nephrotoxicity: A review","volume":"12","author":"Fanos","year":"2000","journal-title":"J. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: The AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/1120009X.2018.1557799","article-title":"Invasive fungal infection in critically ill patients: Hurdles and next challenges","volume":"31","author":"Maseda","year":"2019","journal-title":"J. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: Dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind Common Drug Nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jiac.2018.04.014","article-title":"The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B","volume":"24","author":"Kato","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sacanella, I., Esteve-Pitarch, E., Guevara-Chaux, J., Berrueta, J., Garc\u00eda-Mart\u00ednez, A., G\u00f3mez, J., Casarino, C., Al\u00e9s, F., Canadell, L., and Martin-Loeches, I. (2024). A Real-World Data Observational Analysis of the Impact of Liposomal Amphotericin B on Renal Function Using Machine Learning in Critically Ill Patients. Antibiotics, 13.","DOI":"10.20944\/preprints202407.1002.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02651-16","DOI":"10.1128\/AAC.02651-16","article-title":"Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies","volume":"61","author":"Stanzani","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","first-page":"599","article-title":"Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity","volume":"75","author":"Yokota","year":"2020","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and Amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med. Mycol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e29\u201338","DOI":"10.1086\/505969","article-title":"Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries","volume":"43","author":"Ullmann","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15033","DOI":"10.1038\/s41598-020-72135-y","article-title":"Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan","volume":"10","author":"Takazono","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13771","DOI":"10.1111\/myc.13771","article-title":"Association between the hypokalaemia index based on area over the serum potassium concentration curve and occurrence of acute kidney injury in patients administered liposomal amphotericin B","volume":"67","author":"Ueda","year":"2024","journal-title":"Mycoses"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01876-20","DOI":"10.1128\/AAC.01876-20","article-title":"Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy","volume":"65","author":"Burnett","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cncr.23311","article-title":"Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8629891","DOI":"10.1155\/2019\/8629891","article-title":"Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity","volume":"2019","author":"Personett","year":"2019","journal-title":"Int. J. Nephrol."},{"key":"ref_37","first-page":"206","article-title":"Study Group of Liposomal Amphotericin B in the ICU. Impact of liposomal amphotericin B on renal function in ICU patients","volume":"25","author":"Soriano","year":"2012","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/0886022X.2022.2036618","article-title":"Association between fluid infusions and the recovery from acute kidney injury in patients administered liposomal amphotericin B: A nationwide observational study","volume":"44","author":"Tashiro","year":"2022","journal-title":"Ren. Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/jac\/dkac203","article-title":"Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: A retrospective analysis with propensity score matching","volume":"77","author":"Geersing","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e233072","DOI":"10.1136\/bcr-2019-233072","article-title":"Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B","volume":"13","author":"Koh","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2017.10.018","article-title":"Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis","volume":"90","author":"Yamazaki","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/7\/458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:15:30Z","timestamp":1782533730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/7\/458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jof12070458"],"URL":"https:\/\/doi.org\/10.3390\/jof12070458","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}